Natus Medical Inc (BABY) : First Mercantile Trust Co scooped up 2,288 additional shares in Natus Medical Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 7, 2016. The investment management firm now holds a total of 13,639 shares of Natus Medical Inc which is valued at $561,790.Natus Medical Inc makes up approximately 0.08% of First Mercantile Trust Co’s portfolio.
Other Hedge Funds, Including , Bnp Paribas Arbitrage Sa reduced its stake in BABY by selling 5,550 shares or 53.8% in the most recent quarter. The Hedge Fund company now holds 4,766 shares of BABY which is valued at $192,975. Eqis Capital Management added BABY to its portfolio by purchasing 7,404 company shares during the most recent quarter which is valued at $299,788. Natus Medical Inc makes up approx 0.02% of Eqis Capital Management’s portfolio.
Natus Medical Inc opened for trading at $40.67 and hit $41.32 on the upside on Friday, eventually ending the session at $41.19, with a gain of 1.48% or 0.6 points. The heightened volatility saw the trading volume jump to 1,84,594 shares. Company has a market cap of $1,357 M.
On the company’s financial health, Natus Medical Inc reported $0.39 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.36. The company had revenue of $96.00 million for the quarter, compared to analysts expectations of $92.71 million. The company’s revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.34 EPS.
Many Wall Street Analysts have commented on Natus Medical Inc. The Benchmark Company Initiated Natus Medical Inc on Oct 4, 2016 to “Buy”, Price Target of the shares are set at $55.Natus Medical Inc was Upgraded by Raymond James to ” Outperform” on Sep 13, 2016.
Natus Medical Incorporated (Natus) is a provider of newborn care and neurology healthcare products and services used for the screening diagnosis detection treatment monitoring and tracking of common medical ailments in newborn care hearing impairment neurological dysfunction epilepsy sleep disorders and balance and mobility disorders. The Company offers two product families: Neurology which includes products and services for diagnostic electroencephalography and long term monitoring intensive care unit monitoring electromyography sleep analysis intra-operative monitoring and diagnostic and monitoring transcranial doppler ultrasound technology; and Newborn Care which includes products and services for newborn care including hearing screening brain injury thermoregulation jaundice management and various disposable products as well as products for diagnostic hearing assessment for children through adult populations and others.